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Background: Aberrant AKT activation contributes to gastric cancer cell survival and chemotherapy resistance, however
its regulation is poorly understood. microRNAs have been established to be important regulators in gastric carcinogenesis.
Here, we showed the functional role and putative target of let-7b and let-7g (let-7b/g) in gastric carcinogenesis.
Methods: The expression of let-7b/g in gastric cancer cell lines and primary tumors were evaluated by miRNA qRT-PCR.
The putative target gene of let-7b/g was explored by TargetScan followed by further validation. Functional analyses
including MTT proliferation, monolayer colony formation, cell invasion assays and in vivo study were performed in both
ectopic expression and knockdown approaches.
Results: let-7b/g was found down-regulated in gastric cancer and its downregulation was associated with poor survival
and correlated with lymph node metastasis. let-7b/g inhibited AKT2 expression by directly binding to its 3’UTR, reduced
p-AKT (S473) activation and suppressed expression of the downstream effector pS6. AKT2 mRNA expression showed
negative correlation with the expression of let-7b/g in primary tumors. Short interfering RNA (siRNA) mediated
knockdown of AKT2 phenocopied the tumor-suppressive effects of let-7b/g. Moreover, AKT2 re-expression partly
abrogated the growth-inhibitory effect of let-7b/g.
Conclusion: In conclusion, our findings reveal decreased let-7b/g contributes to aberrant AKT activation in gastric
tumorigenesis and provide a potential therapeutic strategy for gastric cancer.
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Gastric cancer is the fourth most common cancer world-
wide, with an estimated one million new cases per year
[1]. H. pylori is the most important risk factor in gastric
tumorigenesis which induces gastric cancer potentially by
chronic inflammation or through the action of H. pylori
virulence factors such as CagA [2]. Approximately 95%
of gastric cancer are adenocarcinomas by histological
phenotype as intestinal type, diffuse type and mixed/
unclassifiable according to Lauren’s classification [3].
Nowadays, several molecular classifications of gastric* Correspondence: kfto@cuhk.edu.hk
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unless otherwise stated.cancer have been proposed based on the analysis of
whole-genome gene expression studies or deep sequencing
studies [4]. Most gastric cancer patients are diagnosed at
the advanced stage often accompanied with extensive inva-
sion and lymphatic metastasis. Thus the investigations into
the molecular mechanisms involving in gastric cancer
progression become imperative and urgent for targeted
therapy.
microRNAs (miRNAs) are a class of small non-protein-
coding RNAs which have been identified as a new
kind of gene expression regulators through binding to
the 3′ untranslated regions (3′UTRs) of target mRNA,
thus blocking mRNA translation or resulting in mRNA
degradation [5,6]. Emerging evidence shows that miR-
NAs are abnormally expressed in cancer development
and the deregulated miRNAs are associated with tumor
initiation, promotion and progression by regulating
target genes expression [7]. Some miRNAs such asd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and exert oncogenic property in gastric cancer [8-10]. On
the contrary, miR-9, −202-3p, −7 and −206 are down-
regulated and play tumor suppressor function in gastric
carcinogenesis [11-14].
By using miRNA expression microarray, we have iden-
tified aberrantly expressed miRNAs in gastric cancer cell
lines including let-7 family. Compared with normal gastric
epithelium tissue, let-7 family was found to be down-
regulated in all 9 gastric cancer cell lines (Additional file 1:
Table S1), in which let-7a/b/f and let-7c/d/e/g/i were
down-regulated for thousand and hundred times respect-
ively. let-7 microRNA was first identified in gastric cancer
due to its targeting on high mobility group A2 (HMGA2)
[15], a nonhistone chromosomal protein that can modu-
late transcription by altering chromatin architecture. It
has been reported that the expression of let-7 in gastric
cancer correlated with H. pylori infection [16]. Hayashi re-
ported that H. pylori CagA induced aberrant epigenetic si-
lencing of let-7 expression [17]. let-7f, a member of let-7
family, is able to inhibit tumor invasion and metastasis by
targeting MYH9 in human gastric cancer [18]. However,
for let-7b and let-7g (let-7b/g), the possible role and puta-
tive target genes in gastric cancer cells are still not well
elucidated and need investigation.
Materials and methods
Cell line and primary gastric tissues
The information of human gastric cancer cell lines
(MKN1, MKN7, MKN28, MKN45, SNU1, SNU16, AGS,
KatoIII, NCI-N87) were previously described [19]. Cells
were maintained in RPMI 1640 medium (GIBCO, Grand
Island, NY) supplemented with 10% fetal bovine serum
(GIBCO, Grand Island, NY). Among them, AGS (poorly
differentiated and p53-wide type), NCI-N87 (well differen-
tiated and p53-mutation) and MKN45 (with xenograft for-
mation ability) were representatively chosen for functional
studies.
The primary paired samples from gastric cancer patients
were randomly selected from Prince of Wales Hospital
(Year 1999–2010). All participants provided written
consent for the research experiment. Ethical approval
was obtained from the Joint Chinese University of Hong
Kong-New Territories East Cluster Clinical Research
Ethics Committee (CREC Ref. No.2009.521).
RNA extraction and quantitative real-time polymerase
chain reaction (qRT-PCR)
The normal tissue corresponds to Human Stomach Total
RNA commercially available from Ambion (AM7996, Grand
Island, NY). A total of 67 paired (tumor and corresponding
adjacent non-tumorous tissue) RNA samples were achieved
from frozen tissues and 9 paired samples were got from
micro-dissection of paraffin embedded tissues. RNA wasextracted using TRIzol reagent (Invitrogen, Grand Island,
NY). High Capacity cDNA Reverse Transcription Kits
(Applied Biosystems, Grand Island, NY) were used for
cDNA synthesis. qRT-PCR was used to quantitative dif-
ferences in mRNA expression of AKT2 and primers were
as following (sense-Exon 9: CAA AGA TGG CCA CAT
CAA GA; anti-sense-Exon 10: GTC ATT GTC CTC CAG
CAC CT). AKT1 expression were detected using the
following primers (sense-Exon 9: GAG ATT GTG TCA
GCC CTG GA; anti-sense-Exon 10: AGC CCG AAG
TCT GTG ATC TT). The relative expression level was
normalized by RPL29 (sense-Exon 3: GGA CCC CAA
GTT CCT GAG G; anti-sense-Exon 4: GCA TTG TTG
GCC TGC ATC TT) in gastric tissues and B2M (sense-
Exon 1: ACT CTC TCT TTC TGG CCT GG; anti-
sense-Exon 2: ATG TCG GAT GGA TGA AAC CC) in
gastric cancer cell lines [20]. PCR was performed using
SYBR Green PCR reagents (Applied Biosystems) accord-
ing to the manufacturer’s instructions. The reactions were
incubated in a 96-well plate at 95°C for 10 min, followed
by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
For miRNA expression detection, Taqman miRNA as-
says were used to quantify the expression levels of mature
let-7b and let-7g (KIT, 002619 and 002282, Applied Bio-
systems). The relative expression level of microRNAs was
normalized by RNU6B (KIT, 001093, Applied Biosystems).
The reactions were performed in 7500 Fast Real-Time
System (Applied Biosystems) and the reaction mix was
incubated at 95°C for 30 seconds, followed by 40 cycles
of 95°C for 8 seconds and 60°C for 30 seconds.
Protein extraction and Western blot analysis
Protein was extracted from gastric cancer cell lines and
paired primary tissues using RIPA lysis buffer with pro-
teinase inhibitor. Protein concentration was measured by
the method of Bradford (Bio-Rad, Hercules, CA) and 20 μg
of protein mixed with 2 × SDS loading buffer was loaded
per lane, separated by 12% SDS-polyacrylamide gel electro-
phoresis. Protein expression was detected using primary
monoclonal anti-AKT2 antibody (1:1000 dilution, #3063,
Cell Signaling, Danvers, MA), anti-phospho-AKT (S473)
(1:1000 dilution, #9271, Cell Signaling) and anti-pS6
antibody (1:1000, #4858, Cell Signaling). The secondary
antibodies were anti-Mouse IgG-HRP (1:30000, 00049039,
Dako, Glostrup, Denmark) and anti-Rabbit IgG-HRP
(1:10000, 00028856, Dako). The Western blot bands were
quantified by ImageJ.
miRNA/siRNA (small inference RNA) transfection and
functional study
The miRNA precursors, let-7b (PM11050), let-7g
(PM11758), scramble control (AM17110) were purchased
from Applied Biosystems. And siAKT2 (SI00287672 and
SI00287679) were obtained from Qiagen (Valencia, CA).
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Transfection Reagent (Invitrogen) in a 20 nM concentra-
tion for 48 hours followed with functional study and RNA/
protein analysis. Cell proliferation was assessed using
CellTiter 96 Non-Radioactive Cell Proliferation Assay
(Promega, Madison, WI) according to manufacturer’s
instruction. For colony formation assays in monolayer
cultures, the transfected cells were cultured in 6-well
plates for 10 days. Cells were fixed with 70% ethanol
for 15 minutes and stained with 2% crystal violet. The
cell invasion assays using BD Biocoat Matrigel Invasion
Chambers (BD Biosciences, Franklin Lakes, NJ) has been
described previously by W. Kang [21]. The experiment
was performed in triplicate and the mean including SDs
was plotted.
Rescue experiments
let-7b and let-7g precursors together with the negative
control were transfected in AGS, NCI-N87 and MKN45
cells. And 24 hours after precursor transfection, AKT2
expression plasmid (from Addgene, Plasmid #16000)
and empty plasmid (pcDNA3, Life Technologies, Grand
Island, NY) were subsequently transfected with FuGENE
HD Transfection Reagent (Roche, Nutley, NJ). After an-
other 24 hours, cells were collected for functional study
(MTT proliferation assays, monolayer colony formation
assays and in vivo animal model). The experiments were re-
peated for 3 times and the representative data was shown.
Luciferase assays
The annealed oligonucleotides containing the putative
let-7b/g binding site was cloned into pMIR-REPORT
vector (Ambion) via HindIII and SpeI. The sequences of
oligonucleotides were (sense) AGA CAC TAG TTA GCA
CTT CAC ACC CAT TGA and (antisense) GAG AAA
GCT TCT AGA GAT TAC AGG CAT GAG CCA CT).
Mutations located on the predicted seed binding region
were introduced into the luciferase reporter vector using
QuickChange® II Site-Directed Mutagenesis Kit according
to the manufacturer’s instruction. The primer sequences
for mutagenesis were 5′-GTG TGG GCA CAG GCC
TGG GTT CGT GAT CTT TTT AGT GCC TCT C-3′
and 5′-GAG AGG CAC TAA AAA GAT CAC GAA CCC
AGG CCT GTG CCC ACA C-3′. The firefly luciferase
reporter construct and the control Renilla luciferase con-
struct were co-transfected into NCI-N87 cells in 24-well
plates. Cells were harvested after 36 hours for reporter
activity analysis using Dual Luciferase Reporter assays
(Promega, Madison, WI) as described previously [22].
In vivo tumorigenicity study
Total three batches of animal models were used in this
study. For let-7b/g or siAKT2 functional study, MKN45
cells were transfected with let-7b/g precursors or siAKT2together with their control counterparts. The cells (5 × 106
cells suspended in 0.1 ml PBS) were injected subcutane-
ously into the dorsal flank of eight 4-week-old male Balb/c
nude mice. For the rescue in vivo study, MKN45 was
transfected with let-7b/g for 24 hours following by AKT2
or empty vector transfection for another 24 hours. Then
the cells were injected subcutaneously into the dorsal flank
of eight Balb/c nude mice. Tumor diameter was measured
and documented every 4 days until the tumor reached
10 mm in diameter. Tumor volume (mm3) was esti-
mated by measuring the longest and shortest diameter
of the tumor and calculated using the following formula:
volume = (shortest diameter)2 × (longest diameter) × 0.5
[23]. All animal handling and experimental procedures
were approved by Department of Health, Hong Kong
(Reference No: 12–241 in DH/HA&P/8/2/1).
Statistical analysis
The Student T test was employed to compare the func-
tional effect between the target transfectants and the
controls. Expression of let-7b/g and AKT2 (mRNA and
protein) in primary cancerous tissues and their corre-
sponding paired noncancerous tissues were compared by
paired T test. Correlations between let-7b/g expression
and clinicopathologic parameters were assessed by Pearson
correlation analysis. The let-7b/g expression in gastric can-
cer cell lines was compared with it copy number change by
non-parametric Spearman’s rho rank test. The Kaplan-
Meier method was employed to estimate the survival
rates for each variable. The equivalences of the survival
curves were tested by log-rank statistics. All statistical
analysis was performed by SPSS software (version 16.0;
SPSS Inc). A two-tailed P value of less than 0.05 was
considered statistically significant.
Results
The expression of let-7b/g is down-regulated in gastric
cancer and correlates with poor survival
The expression of let-7b/g was measured in gastric can-
cer cell lines and normal stomach epithelium tissue by
miRNA qRT-PCR. let-7b and let-7g were observed down-
regulated in 6 and 7 gastric cancer cell lines respect-
ively compared with normal gastric epithelial sample
(Figure 1A). In a total of 76 paired primary RNA samples,
the expression of let-7b and let-7g showed a decreased
level in tumors compared with the corresponding non-
tumorous gastric mucosal samples (let-7b, P = 0.013;
let-7g, P = 0.003; Figure 1B).
In 76 paired primary samples, let-7b was found down-
regulated in 53 (69.7%) tumor tissues which normalized
by its expression in adjacent normal gastric tissue. Then
two groups were stratified according to the median ex-
pression of let-7b and each group had the same 38 cases.
The low-expression of let-7b group showed a poor survival
Figure 1 let-7b/g is down-regulated in in gastric cancer and correlates with poor survival. (A) The expression of let-7b/g in 9 gastric cancer
cell lines compared with normal gastric epithelium tissue (AM7996). (B) let-7b/g showed a decreased expression in primary gastric tumors
compared with paired adjacent non-tumours tissues (n = 76; let-7b, P = 0.013; let-7g, P = 0.003). (C) Downregulation of let-7b/g predicted
poorer survival in clinical gastric cancer patients (let-7b, P = 0.001; let-7g, P = 0.051).
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of Figure 1C). Meanwhile let-7g showed decreased expres-
sion in 48 (63.2%) tumor tissues when compared with adja-
cent normal tissues and its downregulation also predicted
poorer prognosis in gastric cancer with a marginal signifi-
cant P-value (P = 0.051, lower panel of Figure 1C). We fur-
ther investigated the clinicopathologic correlation of let-7b
and let-7g. Additional file 2: Table S2 summarized the cor-
relation of let-7b/g with other clinicopathologic parameters
in gastric cancer patients. The decreased expression of let-
7b was correlated with lymph node metastasis (P = 0.021).
The let-7g downregulation was also associated with
N-stage (P = 0.044) and lymph node metastasis (P = 0.009),Figure 2 Ectopic expression of let-7b/g exerts tumor suppresser fun
let-7b/g in AGS, NCI-N87 and MKN45 cells (**, P < 0.001). (B) let-7b/g dec
(**, P < 0.001). The experiment was performed in triplicate wells to get sta
(*, P < 0.05; **, P < 0.001). Three random vision fields were selected for invaded
than the negative control group (*, P < 0.05; **, P < 0.001).suggesting that these two miRNAs might be involved in
gastric cancer cell metastasis.
let-7b and let-7g exert tumor suppressor function in
gastric cancer cells
To investigate the functional role of let-7b/g, the precur-
sors of these two miRNAs were transfected into AGS,
NCI-N87 and MKN45 cells. let-7b/g suppressed the growth
of gastric cancer cells AGS, NCI-N87 and MKN45 as dem-
onstrated by a 5-day MTTassay (P < 0.001, Figure 2A). The
tumor suppressor function of let-7b/g was further validated
by monolayer colony formation. A significant reduction of
colony number was observed in let-7b/g transfectantsction in gastric cancer cells. (A) 5-day MTT proliferation results of
reased monolayer colony formation in AGS, NCI-N87 and MKN45 cells
ndard deviations (SDs). (C) let-7b/g inhibited gastric cancer cell invasion
cell counting to get SDs. (D) let-7b/g-MKN45 formed smaller xenografts
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Figure 2B). Ectopic expression of let-7b or let-7g was fur-
ther revealed to inhibit the invasive capacity of gastric
cancer cells as demonstrated by Matrigel invasion as-
says (P < 0.05, Figure 2C). The MKN45 cells with let-
7b/g transfection were injected subcutaneously into
the dorsal flank of nude mice. let-7b/g transfectants
formed smaller xenografts than those scramble trans-
fectants after 22 days (let-7b, P < 0.001; let-7g, P < 0.05;
Figure 2D).
let-7b and let-7g decrease AKT2 expression by direct
binding with its 3′UTR
AKT2 was predicted to be a putative target of let-7b/g by
TargetScan (www.targetscan.org). The putative bindingFigure 3 let-7b/g targets AKT2 in gastric cancer. (A) The binding sites of le
(B) AKT2 mRNA expression was down-regulated upon ectopic let-7b/g expressi
and pS6 upon let-7b/g ectopic expression in AGS, NCI-N87 and MKN45 cells. (D
site or mutated binding site of AKT2 3′UTR after let-7b/g transfection (Wild type
Mutation, the binding site was mutated; *, P< 0.05).sites of let-7b/g within the 3′UTR of AKT2 were shown
in Figure 3A. We transfected let-7b/g into gastric cancer
cells and decreased AKT2 mRNA expression level was ob-
served in AGS, NCI-N87 and MKN45 cells (P < 0.05; left
bar chart of Figure 3B). However, ectopic expression of
let-7b/g did not change the AKT1 mRNA expression
(right bar chart of Figure 3B), indicating let-7b/g only ex-
erts its inhibitory effect on AKT2 but not on AKT1.
AKT2 protein showed a decrease expression after ectopic
let-7b/g expression (Figure 3C), suggesting that let-7b/g
triggered a silencing effect on the endogenous AKT2 ex-
pression. Meanwhile, the phosphorylated AKT (S473) and
its direct downstream effector of AKT-mTOR pathway,
pS6, showed decreased expression upon let-7b/g overex-
pression. A luciferase reporter assay was performed tot-7b/g on the AKT2 3′UTR as predicted by TargetScan (www.targetscan.org).
on (*, P< 0.05; **, P< 0.001). (C) Western blot analysis of AKT2, p-AKT (S473)
) Relative luciferase activity in the constructs containing wild-type binding
, the construct containing the complementary sequence of seed region;
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shown in Figure 3D, let-7b/g decreased the relative lu-
ciferase activity of constructs encompassing AKT2 3′
UTR binding sites in NCI-N87 cells (P < 0.05). Mean-
while, let-7b/g did not suppress the luciferase activity
in the constructs containing the mutated binding site.
The results in this part revealed that let-7b/g specifically
recognized the binding sites in AKT2 3′UTR and directly
repressed AKT2 expression through mRNA degradation
and protein synthesis inhibition.
AKT2 is up-regulated in gastric cancer and shows
negative correlation with let-7b/g
Expression of AKT2 mRNA was up-regulated in 8 gastric
cancer cell lines except SNU1 compared with normal gas-
tric mucosal sample (Figure 4A). In 28 pairs of primary
gastric cancers, AKT2 mRNA expression showed upregu-
lation in 19 (67.9%) tumor samples by normalization with
its expression in adjacent non-tumorous tissues. The ex-
pression of AKT2 in the cancer tissues showed higher
expression than it expression in adjacent normal gastric
tissues (P = 0.034, Figure 4B). Strong AKT2 protein ex-
pression can be strongly detected in all 9 gastric cancer
cell lines but only one normal gastric mucosal tissue
showed week AKT2 protein expression (Figure 4C). In 28
paired primary protein samples, AKT2 protein expression
showed up-regulated in the cancer tissues compared
with adjacent non-tumorous tissues after quantification
(P = 0.001, Figure 4D). We then examined the AKT2
mRNA and let-7b/g expression in 28 paired primary
gastric cancer samples. The AKT2 mRNA expression
was negatively correlated with let-7b/g expression (let-7b,
P = 0.001; let-7g, P = 0.021; Figure 4E), suggesting let-7b/g
downregulation might be, at least partly, responsible for
the aberrant activation of AKT2 in gastric cancers.
siRNA-mediated knockdown of AKT2 phenocopies the
tumor-suppressive effect of let-7b/g
We have demonstrated that let-7b/g targeted AKT2 and
exerted tumor suppressor function in gastric cancer. siRNA-
mediated AKT2 knockdown was therefore performed
to investigate if AKT2 downregulation phenocopied the
tumor-suppressive effect of let-7b/g. We transfected siAKT2
into gastric cancer cell lines AGS, NCI-N87 and MKN45.
Successful AKT2 knockdown was confirmed by Western
blot analysis. p-AKT (S473) and pS6 protein showed
decreased expression upon siAKT2 transfection (Figure 5A).
AKT2 knockdown suppressed AGS, NCI-N87 and MKN45
cell proliferation in a 5-day MTT assays (P < 0.001,
Figure 5B). AKT2 knockdown also decreased monolayer
colony formation in gastric cancer cells to a significant
level (Figure 5C). Moreover, siAKT2 inhibited cell invasion
of gastric cancer cells (P < 0.001, Figure 5D). The effect of
siAKT2 on tumor growth in vivo was also investigated.The siAKT2-MKN45 and vector control cells were injected
into nude mice subcutaneously. The tumor growth in
siAKT2 groups was significantly decreased compared with
the vector control after 22 days (P < 0.05, Figure 5E).
AKT2 re-expression abrogated the growth-inhibitory
effect of let-7b/g
Since AKT2 is a predicted target of let-7b/g, we further
investigated if AKT2 re-expression diminished the sup-
pressive phenotype change caused by let-7b and let-7g.
Interestingly, we found that the growth inhibitory effect of
let-7b/g were partially abrogated by AKT2 re-expression
(MTT proliferation assays, Figure 6A; monolayer colony
formation assays, Figure 6B), suggesting AKT2 was func-
tionally involved in let-7b/g-inducing suppression of
gastric cancer cell growth. In vivo experiments yielded
similar results. Cells co-transfected with let-7b/g and
AKT2 formed bigger xenografts than those with let-
7b/g alone (P < 0.001, Figure 6C).
Discussion
let-7 family, which has 10 mature subtypes identified
(from 7a to 7i, miR-98 and miR-202), is closely associated
with normal development and human cancers [24]. LIN28
and LIN28B have been found to act as post-transcriptional
repressors of let-7 biogenesis by binding with the loop
portion of the pri-let-7 hairpin and the stem of pre-let-7
to inhibit its binding with Drosha or Dicer [25]. Genomic
DNA copy number alterations [26] and DNA methylation
[27] are also responsible for the decreased expression of
let-7 family in cancers. In 9 gastric cancer cells, we com-
pared let-7b (in 22q13) and let-7g (in 3p21) expression
with the DNA copy number change of their loci and found
although the P-value is not significant due the limited
number of cell lines, let-7b/g expression showed a trend of
positive correlation with their array-CGH results (let-7b,
P = 0.205; let-7g, P = 0.088; Additional file 3: Figure S1).
The let-7 miRNA family is involved in the proliferation,
apoptosis and invasion of cancer cells. A number of stud-
ies have reported that let-7 is down-regulated and acts as
a tumor suppressor in kinds of cancer types, including non-
small cell lung carcinoma [28], breast cancer [29], prostate
cancer [30], nasopharyngeal carcinoma [31], hepatocellular
carcinoma [32] and esophageal squamous cell carcinoma.
Several oncogenes and signaling pathways, such as RAS
oncogene, c-Myc [33], HMGA2 [15] and JAK-STAT3
pathway [24], are the main targets of let-7 in carcino-
genesis. In addition, SNP rs61764370 in KRAS 3′UTR
(T. > G) promotes cell proliferation through downregu-
lation of let-7a/b/c [34]. In current study, we not only
confirmed the tumor suppressor function of let-7b/g
but also revealed a novel functional target of let-7
family, AKT2, together with the dysregulated signaling
pathway, AKT2-mTOR-pS6. Ectopic expression of let-7b/g
Figure 4 AKT2 is over-expressed in gastric cancer. (A) The expression of AKT2 mRNA in 9 gastric cancer cell lines compared with normal gastric
tissue. (B) AKT2 mRNA showed increased expression in gastric tumor tissues compared with adjacent non-cancerous tissues (n = 28, P = 0.034).
(C) Western blot analysis of AKT2 in 9 gastric cancer cell lines and 3 normal gastric tissues. (D) The protein expression of AKT2 in 28 paired primary tumors
(N, paired non-tumorous tissue; T, tumor tissue). The AKT2 protein expression in gastric cancer tissues was up-regulated compared with
adjacent non-tumorous tissues by quantification (P = 0.001). (E) AKT2 mRNA expression showed negative correlation with let-7b/g expression in primary
tumors (n = 28; let-7b, P = 0.001; let-7g, P = 0.021).
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addition, AKT2 re-expression alleviated the suppressive
phenotypes of let-7b/g, thus establishing their functionalinteraction. More importantly in primary samples, AKT2
mRNA expression showed a negative correlation with
let-7b/g expression, suggesting that let-7b/g exerts its
Figure 5 (See legend on next page.)
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Figure 6 AKT2 re-expression rescues the inhibitory effect of let-7b/g. (A) AKT2 re-expression partly abolished the growth-inhibitory effect of
let-7b/g in a 5-day MTT assays (*, P < 0.05; **, P < 0.001). The SDs were achieved by the 575 nm absorbance readings in 6 wells of each item.
(B) AKT2 abrogated the suppressed monolayer colony formation by let-b/g (*, P < 0.05; **, P < 0.001). The experiments was performed in triplicate wells
to get SDs. (C) AKT2 re-expression promoted in vivo tumor growth (**, P < 0.001).
(See figure on previous page.)
Figure 5 AKT2 knockdown phenocopies the tumor-suppressive effect of let-7b/g in gastric cancer cells. (A) Western blot of AKT2, p-AKT
(S473) and pS6 after siAKT2 transfection in AGS, NCI-N87 and MKN45 cells. (B) AKT2 knockdown suppressed cell proliferation (**, P < 0.001). 6 wells
were measured for each group to get SDs. (C) AKT2 knockdown decreased monolayer colony formation in AGS, NCI-N87 and MKN45 cells (**, P< 0.001). The
experiments was repeated in 3 wells to get SDs. (D) siAKT2 inhibited cell invasion of gastric cancer cells (**, P< 0.001). The invaded cells in 3 random vision
fields were counted for SDs achieving. (E) siAKT2 suppressed the formation of xenografts in nude mice compared with siScramble group (*, P< 0.05).
Kang et al. Journal of Translational Medicine 2014, 12:281 Page 10 of 12
http://www.translational-medicine.com/content/12/1/281
Kang et al. Journal of Translational Medicine 2014, 12:281 Page 11 of 12
http://www.translational-medicine.com/content/12/1/281tumor suppressor function in gastric carcinogenesis at
least by partly down-regulating AKT2. All these findings
in this part revealed the critical role of let-7b/g in molecu-
lar gastric carcinogenesis.
AKT2, a member of Protein Kinase B family, is an im-
portant signaling molecule in the insulin signaling path-
way. It has been identified as an oncogene and amplified
in human ovarian carcinomas [35], pancreatic carcinomas
[36] and pancreatic ductal adenocarcinomas [37]. AKT2 is
a link between the metabolic action of insulin signal trans-
duction and tumorigenesis in liver malignancies [38]. As a
major downstream effector of PI3K/AKT survival path-
way, AKT2 expression markedly increased the incidence
of pulmonary metastases in breast tumor model [39].
AKT2 knockdown by RNA interference suppresses cell
proliferation and induces apoptosis even increases che-
mosensitivity in lung adenocarcinoma [40], malignant
gliomas [41,42], pancreatic cancer [43] and ovarian can-
cer [44]. We showed that AKT2 was upregulated in gastric
cancer and its knockdown suppressed gastric cancer cell
proliferation, reduced monolayer colony formation and
inhibited xenograft formation in vivo, resembling the
tumor-suppressive effects of let-7b/g in gastric cancer cells.
In conclusion, our results underscore let-7b/g as import-
ant tumor-suppressive miRNAs in gastric cancer cells by
directly targeting AKT2. All these findings support that
the frequently down-regulated let-7b/g contributes to acti-
vation of AKT2 and gastric carcinogenesis which might
has therapeutic potential in gastric cancer.Additional files
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